fondation pour la dermatite atopique · pdf file 2016. 7. 21. · la fondation pour...

Click here to load reader

Post on 05-Feb-2021

2 views

Category:

Documents

0 download

Embed Size (px)

TRANSCRIPT

  • Une fondation pour les professionnels de santé Une fondation pour les patients atteints de dermatite atopique

    Fondation pour la Dermatite Atopique Recherche et Education

  • Les missions

    Les membres fondateurs

    Pierre Fabre Dermocosmétique Laboratoires A-Derma Laboratoires Dermatologiques Avène Pierre Fabre Dermatologie Laboratoires Dermatologiques Ducray Laboratoires Klorane Pierre Fabre Médicament

    Le Conseil d’Administration

    Collège de Professeurs

    Professeur Yves De Prost (Paris)

    Professeur François Bernard Michel (Montpellier)

    Professeur Jean Revuz (Paris)

    Conseil Scientifi que

    Professeur Carle Paul (Hôpital Larrey - Toulouse)

    Professeur Jean-François Nicolas (Centre Hospitalier - Lyon Sud)

    Professeur Jean-François Stalder (Hôtel Dieu - Nantes)

    La Fondation pour la Dermatite Atopique est une

    fondation d’entreprise Pierre Fabre exclusivement

    dédiée à l’eczéma atopique

    Les projets de recherche fondamentale ou clinique peuvent faire l’objet d’un soutien fi nancier après validation par le Conseil Scientifi que de la Fondation.

    Comme toutes les maladies chroniques, la dermatite atopique est diffi cile à prendre en charge. Le découragement gagne souvent enfants et parents qui ne comprennent pas toujours comment tirer le meilleur parti des traitements disponibles. L’éducation thérapeutique met en œuvre des moyens adaptés pour apporter les connaissances nécessaires, un savoir-faire et un savoir-être précieux.

    La Fondation pour la Dermatite Atopique aide le développement des centres d’éducation thérapeutique.

    Une fondation pour la recherche

    Une fondation pour l’éducation thérapeutique

    Les missions

  • Aider la recherche dans le domaine de la dermatite atopique

    Aider la recherche

    PO SCORAD ORIGINAL ARTICLE SKIN AND EYE DISEASES

    Patient-Oriented SCORAD (PO-SCORAD): a new self- assessment scale in atopic dermatitis validated in Europe J.-F. Stalder1, S. Barbarot1, A. Wollenberg2, E. A. Holm3, L. De Raeve4, S. Seidenari5, A. Oranje6, M. Deleuran7, F. Cambazard8, A. Svensson9, D. Simon10, E. Benfeldt11, T. Reunala12, J. Mazereeuv13, F. Boralevi14, B. Kunz15, L. Misery16, C. G. Mortz17, U. Darsow18, C. Gelmetti19, T. Diepgen20, J. Ring18,21, M. Moehrenschlager21, U. Gieler22 & A. Taı̈eb14, for the PO-SCORAD Investigators Group*

    Department of Dermatology, Nantes University Hospital, Nantes, France; Department of Dermatology and Allergy, Ludwig-Maximilian Univer-

    sity, Munich, Germany; Skin Clinic in Ballerup, ‘‘Helsehuset’’, Ballerup, Denmark; Department of Dermatology UZ Brussels, Vrije Universiteit

    Brussel, Brussel, Belgium; Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy; University Hospital

    Rotterdam and Erasmus University, Rotterdam, the Netherlands; Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark;

    Jean Monet Faculty, Saint-Etienne, France; Department of Dermatology, Skane University Hospital, Malmö, Sweden; Department of

    Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; Department of Dermato-allergology, Copenhagen

    University Hospital Gentofte, Hellerup, Denmark; Medical School, Tampere University, Tampere, Finland; Department of Dermatology and

    Paul Sabatier University, Larrey Hospital, Toulouse, France; Department of Dermatology and Pediatric Dermatology, St André Hospital,

    Bordeaux, France; Dermatologikum Hamburg, Hamburg, Germany; Department of Dermatology, Brest University Hospital, Brest, France;

    Department of Dermatology and Allergy centre, Odense University Hospital, Odense, Denmark; Deptartment of Dermatology and Allergy

    Biederstein, Technische Universität München and Division of Environmental Dermatology and Allergy, Helmholtz Center/Tum, Munich, Ger-

    many; Department of Anesthesia, Intensive care and Dermatologic Sciences, Fondazione Ca’ Granda ‘‘Ospedale Maggiore Policlinico’’, Milan,

    Italy; University Hospital Heidelberg, Department of Social Medicine, Center of Occupational & Environmental Dermatology, Heidelberg,

    Germany; Hochgebirgsklinik Davos-Wolfgang, Christine-Kuehne Centre for Allergy Research and Education (CK-CARE), Davos, Switzerland;

    Department of Psychosomatic Medicine-Psychodermatology, University of Giessen, Giessen, Germany

    To cite this article: Stalder J-F, Barbarot S, Wollenberg A, Holm EA, De Raeve L, Seidenari S, Oranje A, Deleuran M, Cambazard F, Svensson A, Simon D,

    Benfeldt E, Reunala T, Mazereeuv J, Boralevi F, Kunz B, Misery L, Mortz CG, Darsow U, Gelmetti C, Diepgen T, Ring J, Moehrenschlager M, Gieler U, Taı̈eb A,

    for the PO-SCORAD Investigators Group. Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe. Allergy

    2011; 66: 1114–1121.

    Keywords

    atopic dermatitis (MesH); eczema score;

    patient-oriented; SCORing of Atopic

    Dermatitis index; self-assessment score.

    Correspondence

    Pr. Jean-François Stalder, Service de

    Dermatologie, CHU de Nantes, Hôtel Dieu,

    44035 Nantes, France.

    Tel.: +33-2-40-08-31-15

    Fax: +33-2-40-08-31-17

    E-mail: jean-francois.stal[email protected]

    *The PO-SCORAD investigator group is

    listed in the Acknowledgments section

    Accepted for publication 12 February 2011

    DOI:10.1111/j.1398-9995.2011.02577.x

    Edited by: Hans-Uwe Simon

    Abstract

    Background: Patient-oriented medicine is an emerging concept, encouraged by the World

    Health Organization, to greater involvement of the patient in the management of chronic

    diseases. The Patient-Oriented SCORing Atopic Dermatitis (PO-SCORAD) index is a

    self-assessment score allowing the patient to comprehensively evaluate the actual course

    of atopic dermatitis (AD), using subjective and objective criteria derived mainly from the

    SCORAD, a validated AD severity clinical assessment tool.

    Objectives: To validate the PO-SCORAD index in a large European population of

    patients exhibiting all forms of AD severity by assessing its correlation with the

    SCORAD index.

    Patients/methods: Four hundred and seventy-one patients (185 adults, 286 children) con-

    sulting for AD in hospitals from 9 European countries were recruited. The investigators

    and the patients used the SCORAD and PO-SCORAD scales, respectively, to assess AD

    severity at inclusion (D0) and 28 ± 7 days later (D28).

    Results: Patient-Oriented SCORing Atopic Dermatitis and SCORAD scores were signifi-

    cantly correlated at D0 [r = 0.67 (95% CI: 0.62; 0.72), P < 0.0001]. Consistency was con-

    firmed at D28, with a stronger linear correlation between both scales [r = 0.79 (95% CI:

    0.75; 0.83), P < 0.0001]. Absolute changes from baseline in SCORAD and PO-SCORAD

    scores were also significantly correlated [r= 0.71 (95% CI: 0.64; 0.76), P < 0.0001].

    Although no specific intervention was investigated, AD improved over the study, with a

    decrease of PO-SCORAD and SCORAD scores from D0 to D28 by )19.19% and )24.39%, respectively. The consistency of the correlations was similar in the adult and children groups.

    Conclusions: This study validated the use of PO-SCORAD to self-assess AD severity

    and demonstrated its good correlation with SCORAD.

    Allergy

    1114 Allergy 66 (2011) 1114–1121 ª 2011 John Wiley & Sons A/S

    Etude sur les récepteurs à l’histamine

    Etude sur la corticophobie

    Experimental dermatology • Original article CED Clinical and Experimental Dermatology

    CPD

    Association between copy-number variations of the human histamine H4 receptor gene and atopic dermatitis in a Chinese population

    B. Chen,1 T. Ye,1,2,3 Y. Shao,1,2,3 J. Zhang,1,2,3 Q. Zhong,1,2,3 X. Hu,1,2,3 W. Zhang4 and B. Yu1,2,3

    Dermatology Department and Shenzhen Key Discipline of Dermatology, Peking University Shenzhen Hospital, Shenzhen, China; Shenzhen Key

    Laboratory for Translational Medicine of Dermatology and Biomedical Research Institute, Shenzhen PKU-HKUST Medical Center, Shenzhen, China

    doi:10.1111/ced.12117

    Summary Background. Atopic dermatitis (AD) is a chronic, relapsing allergic skin disease. The histamine H4 receptor (HRH4) has been shown to be associated with a number

    of autoimmune disorders, including AD.

    Aim. To explore a possible association between copy-number variations (CNVs) of

    the HRH4 gene and the risk of AD in a Chinese population.

    Methods. Genomic DNA and RNA were collected from 541 patients with AD and

    613 healthy controls, and the CNVs and mRNA levels of HRH4 were examined.

    ELISA was used to measure the levels of IgE in all participants.

    Results. Amplifications of HRH4 copy numbers were associated with the risk of

    developing AD (P < 0.05, OR = 1.85, 95% CI 1.30–2.63), whereas deletions of HRH4 copy numbers were not associated with disease risk for AD (P = 0.30, OR = 0.82, 95% CI 0.57–1.19). HRH4 mRNA levels were much higher in samples with HRH4 copy-number amplifications than in those without such amplifications (P < 0.05). IgE levels were associated with amplifications (P < 0.05, OR = 1.96, 95% CI 1.19–3.25), but not with deletions (P = 0.63, OR = 0.87, 95% CI 0.49–1.54) of HRH4 copy numbers.

    Conclusions. CNVs of the HRH4 gene are associated with AD in a